Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
(Correction) Partial Correction to “Second Half, Fiscal Year Ending May 2026 Financial Results Presentation Materials”
Summary of Consolidated Financial Results for the Six Months Ended November 30, 2025 (Under Japanese GAAP)
Second Half, Fiscal Year Ending May 2026 Financial Results Presentation Materials
Daito Pharma, First Half Ordinary Profit Increases by 20%, Sep-Nov Ordinary Profit Increases by 46%
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Notice Regarding the Results and Completion of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNeT-3)
Notice Regarding Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase (ToSTNeT-3) and Cancellation of Treasury Shares
Daito Pharma, Jun-Aug (1Q) Ordinary Profit Increases by 7%
Summary of Consolidated Financial Results for the Three Months Ended August 31, 2025 (Under Japanese GAAP)
1Q Fiscal Year Ending May 2026 Financial Results
Notice Regarding the Acquisition of Treasury Shares and the Cancellation of Treasury Shares
Fiscal Year Ended May 2025 Full-Year Financial Results
Notice Regarding Introduction of Shareholder Special Benefit Plan
Summary of Consolidated Financial Results for the Fiscal Year Ended May 31, 2025 (Under Japanese GAAP)
Daito Pharma, 11% Increase in Ordinary Profit for The Current Fiscal Year, Dividend Effectively Increased
Notice of Candidate Selection for New Director, Board Changes, and Executive Officer Changes
Notice Regarding the Completion of Cancellation of Treasury Shares
Meiji Seika Pharma and Daito Pharma Initiate Dialogue on Collaboration Toward Establishing a Novel Consortium for the Realignment of Gx Pharma Mfg.